Clinical Pharmacokinetics

, Volume 50, Issue 12, pp 773–779

Kinetic Nomograms Assist Individualization of Drug Regimens

  • Hafedh Marouani
  • Anastasios Zografidis
  • Athanassios Iliadis
Original Research Article

Abstract

Background and Objectives: Therapeutic drug monitoring is applied to a range of drugs. To predict an appropriate dosing regimen, models based on Bayesian techniques have been used. However, this approach requires a well trained professional and sophisticated software. The objectives of this study were first to develop kinetic nomograms as a useful tool to achieve individual drug blood concentrations within the therapeutic window, using few samples and in a short period of time; and second to evaluate the performance of these nomograms in dosage adjustment and compare them with the Bayesian procedure by use of simulation.

Methods: Kinetic nomograms involve collection of concentration-time profiles following repeated administrations of a fixed identification protocol and targeting of a steady-state concentration. The profiles divide the concentration-time space into several areas, each of them corresponding to a given adjusted drug dose. Kinetic nomograms are grounded on the statistical description of the interindividual variability provided by population pharmacokinetic approaches. To use them, the assayed drug concentration in a blood sample is first located in the kinetic nomogram and then the dose corresponding to the area containing this location is read. Evaluation of performance and comparison with the traditional Bayesian procedure were done by a simulation study using the immunosuppressant drug sirolimus (rapamycin). All calculations were performed by use of Matlab software.

Results: The simulation study confirmed the need for individual dosage adjustment; 71.6% of individuals underwent modification of the identification protocol of 1 mg twice daily in order to reach steady-state trough concentrations of 8 ng/mL. When the regimens were adjusted by kinetic nomograms and the Bayesian procedure, the steady-state trough concentrations of sirolimus showed low variability (coefficients of variation [CVs] of 23.4% and 24.0%, respectively) as compared with those obtained by standard recommended protocols of 4mg once daily (CV 68.6%). The doses adjusted by kinetic nomograms and the Bayesian procedure were linearly linked and highly correlated (r = 0.96), and both provided simultaneous control of minimum and maximum drug concentrations (63.9% and 68.7% of cases between 6 and 20 ng/mL, respectively).

Conclusion: Kinetic nomograms allow rapid and reliable dosage adjustment after the start of drug therapy. They are interesting alternatives to the cumbersome Bayesian procedure, and they provide dosage adjustment even for drugs that exhibit large intraindividual variability. In the clinical context, kinetic nomograms render individual dosage adjustment a simplified bedside application, and they could assist population studies aiming at dose individualization.

References

  1. 1.
    Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med 2009; 24(1): 1–10PubMedCrossRefGoogle Scholar
  2. 2.
    Spector R, Park GD, Johnson GF, et al. Therapeutic drug monitoring. Clin Pharmacol Ther 1988; 43: 345–53PubMedCrossRefGoogle Scholar
  3. 3.
    Alnaim L. Therapeutic drug monitoring of cancer chemotherapy. J Oncol Pharm Pract 2007; 13(4): 207–21PubMedCrossRefGoogle Scholar
  4. 4.
    Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol 2002; 16(4): 253–62PubMedCrossRefGoogle Scholar
  5. 5.
    Rousseau A, Leger F, LeMeur Y, et al. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Ther Drug Monit 2004; 26(1): 23–30PubMedCrossRefGoogle Scholar
  6. 6.
    Eldesoky E, Meinshausen J, Bühl K, et al. Generation of pharmacokinetic data during routine therapeutic drug monitoring: Bayesian approach vs pharmacokinetic studies. Ther Drug Monit 1993; 15(4): 281–8CrossRefGoogle Scholar
  7. 7.
    Steimer JL, Vozeh S, Racine-Poon A, et al. The population approach: rationale, methods, applications in clinical pharmacology and drug development. In: Welling PG, Balant LP, editors. Pharmacokinetics of drugs, handbook of experimental pharmacology. Berlin: Springer-Verlag, 1994: 405–51CrossRefGoogle Scholar
  8. 8.
    Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992; 22(6): 447–67PubMedCrossRefGoogle Scholar
  9. 9.
    Birkett DJ. Therapeutic drug monitoring. Australian Prescriber 1997; 20: 9–11Google Scholar
  10. 10.
    Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol 2001; 52(Suppl. 1): 5–10CrossRefGoogle Scholar
  11. 11.
    Musuamba FT, Rousseau A, Bosmans JL, et al. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. Clin Pharmacokinet 2009; 48(11): 745–58PubMedCrossRefGoogle Scholar
  12. 12.
    Kawamata S, Sakaida H, Hori T, et al. The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines. Blood 1998; 91(2): 561–9PubMedGoogle Scholar
  13. 13.
    Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002; 24(3): 330–50PubMedCrossRefGoogle Scholar
  14. 14.
    Holt DW, Denny K, Lee TD, et al. Therapeutic monitoring of sirolimus: its contribution to optimal prescription. Transplant Proc 2003; 35(3 Suppl.): 157–61CrossRefGoogle Scholar
  15. 15.
    Oellerich M, Armstrong VW, Streit F, et al. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. Clin Biochem 2004; 37(6): 424–8PubMedCrossRefGoogle Scholar
  16. 16.
    Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 2005; 28(2): 153–81PubMedCrossRefGoogle Scholar
  17. 17.
    Aspeslet LJ, Yatscoff RW. Requirements for therapeutic drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation. Clin Ther 2000; 22(Suppl. B): 86–92CrossRefGoogle Scholar
  18. 18.
    Meier-Kriesche HU, Kaplan B. Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations. Clin Ther 2000; 22(Suppl. B): 93–100CrossRefGoogle Scholar
  19. 19.
    Zimmerman JJ. Exposure-response relationships and drug interactions of sirolimus. AAPS J 2004; 6(4): e28PubMedCrossRefGoogle Scholar
  20. 20.
    Cattaneo D, Merlini S, Pellegrino M, et al. Therapeutic drug monitoring of sirolimus: effect of concomitant immunosuppressive therapy and optimization of drug dosing. Am J Transplant 2004; 4(8): 1345–51PubMedCrossRefGoogle Scholar
  21. 21.
    Djebli N, Rousseau A, Hoizey G, et al. Sirolimus population pharmacokinetic/pharmacogenetic analysis and Bayesian modelling in kidney transplant recipients. Clin Pharmacokinet 2006; 45(11): 1135–48PubMedCrossRefGoogle Scholar
  22. 22.
    Iliadis A, Bruno R, Cano JP. Steady-state dosage regimen calculations in linear pharmacokinetics. Int J Biomed Comput 1986; 18: 167–82PubMedCrossRefGoogle Scholar
  23. 23.
    Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357(25): 2562–75PubMedCrossRefGoogle Scholar
  24. 24.
    Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74(8): 1070–6PubMedCrossRefGoogle Scholar
  25. 25.
    Watson CJE, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005; 5(10): 2496–503PubMedCrossRefGoogle Scholar
  26. 26.
    Iliadis A, Brown AC, Huggins ML. APIS: a software for identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics. Comput Methods Programs Biomed 1992; 38(4): 227–39PubMedCrossRefGoogle Scholar
  27. 27.
    MathWorks Inc. Matlab: high-performance numeric computation and visualization software (version 7.0). Natick (MA): MathWorks Inc., 2004Google Scholar
  28. 28.
    Silverman BW. Density estimation for statistics and data analysis. London: Chapman and Hall, 1992Google Scholar
  29. 29.
    Evans WE, Schentag JJ, Jusko WJ. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver (WA): Applied Therapeutics; 1992Google Scholar
  30. 30.
    Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000; 14(2): 97–109PubMedCrossRefGoogle Scholar
  31. 31.
    Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 2001; 28(8): 743–51PubMedCrossRefGoogle Scholar
  32. 32.
    Stanford BL, Shah SR, Ballard EE, et al. A randomized trial assessing the utility of a test-dose program with taxanes. Curr Med Res Opin 2005; 21(10): 1611–6PubMedCrossRefGoogle Scholar
  33. 33.
    Ferron GM, Mishina EV, Zimmerman JJ, et al. Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther 1997; 61(4): 429–41CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Hafedh Marouani
    • 1
  • Anastasios Zografidis
    • 2
  • Athanassios Iliadis
    • 1
  1. 1.Faculty of PharmacyMediterranée UniversityMarseillesFrance
  2. 2.School of PharmacyUniversity of AthensAthensGreece
  3. 3.Department of PharmacokineticsFaculty of PharmacyMarseille CEDEX 5France

Personalised recommendations